Can Foundayo cause low blood sugar? On its own, uncommonly. Foundayo (orforglipron) is a GLP-1 receptor agonist, and its UK Summary of Product Characteristics (SmPC) describes a glucose-dependent action: in animal studies orforglipron "increased insulin secretion in a glucose-dependent manner". The patient leaflet puts it plainly: Foundayo "reduces the level of sugar in the body only when the levels of sugar are high". The picture changes alongside insulin or a sulfonylurea.

It is information only, not medical advice: Foundayo is a prescription-only medicine, and a prescriber decides whether it suits you and what happens to your other diabetes medicines. The wider profile is in our Foundayo side effects guide, other combinations in Foundayo drug interactions.

Key takeaway: the label's hypoglycaemia warning is about combinations. The leaflet lists low blood sugar as very common with insulin, common with a sulfonylurea and uncommon without either, all measured in people with type 2 diabetes. On insulin or a sulfonylurea, settle the dose question with the prescriber first.

Foundayo and low blood sugar: why the risk on its own is low

A hypo is usually a blood glucose below 4 mmol/L, says the NHS; it mostly affects people with diabetes on insulin or certain other diabetes medicines and is rare without diabetes. The SmPC credits orforglipron's glucose-lowering to "increased glucose dependent insulin secretion", lower fasting glucagon and better insulin sensitivity: the extra insulin comes when glucose is high (see how orforglipron works).

Insulin and sulfonylureas: what the SmPC asks prescribers to do

Section 4.4 says patients taking orforglipron "in combination with an insulin secretagogue (for example, a sulfonylurea) or insulin may have an increased risk of hypoglycaemia". Section 4.2 gives the instruction: "a reduction in the dose of sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia. Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea and/or insulin. A stepwise approach to insulin reduction is recommended."

A secretagogue prompts insulin release; if unsure whether a diabetes tablet is a sulfonylurea, ask a pharmacist (the NHS names gliclazide and glimepiride among medicines that can cause hypos). Metformin and SGLT2 inhibitors are different: section 4.5 says their current dose "can be continued". The leaflet adds that your doctor may reduce the insulin or sulfonylurea dose before you start, and that you should test your blood glucose as instructed.

How often hypos happened in the trials

Section 4.8 separates the trial populations, and the trials used capsules (6 mg capsule = 5.5 mg tablet).

  • People with type 2 diabetes in a weight-management trial: clinically significant hypos (below 3.0 mmol/L or severe) in 2% on orforglipron versus 0.2% on placebo. One person on the 6 mg capsule had a severe episode, and the SmPC says "severe hypoglycaemia with orforglipron cannot be excluded". In the trial's 388-patient sulfonylurea subset, 6.7% of those on orforglipron reported hypoglycaemia (none severe), against 0.5% of patients not taking a sulfonylurea.
  • Type 2 diabetes, orforglipron alone: clinically significant hypos in 0.7% to 1.4% versus 0.7% on placebo; no severe episodes.
  • Type 2 diabetes with insulin glargine: 12.9% to 19.0% versus 20.7% on placebo; severe in three patients on orforglipron.
  • People without diabetes: the SmPC gives no figure. Its "uncommon" rating for hypoglycaemia without insulin or a sulfonylurea (up to 1 in 100) is footnoted as applying to patients with type 2 diabetes.

Symptoms, and why they are easy to confuse

The NHS lists hunger, dizziness, anxiety or irritability, sweating, shaking, tingling lips, palpitations, tiredness or weakness, blurred vision and confusion; a severe hypo can cause a seizure or unconsciousness. Dizziness, headache, a fast pulse and tiredness are also common Foundayo side effects in their own right, so check your blood sugar if you can, the NHS says.

What to do about a hypo: the NHS steps

For someone with diabetes with symptoms or a reading below 4 mmol/L, the NHS steps are:

  1. Take something that raises blood sugar quickly: a small glass of fruit juice or sugary fizzy drink, five glucose tablets, four large jelly babies or two tubes of glucose gel.
  2. Check after 10 to 15 minutes; if still below 4 mmol/L, repeat and check again after 10 minutes.
  3. Once above 4 mmol/L, eat something longer-lasting: biscuits, a sandwich or the next meal if due.

If someone is unconscious: no food or drink, the recovery position, glucagon if available and you know how. Call 999 if they are unconscious or not responding normally and there is no glucagon or no one able to give it, no recovery within 10 minutes of it, or alcohol is involved.

Driving: the DVLA rules that apply

Section 4.7 says that with a sulfonylurea or insulin, "patients must be advised to take precautions to avoid hypoglycaemia while driving and using machines". The DVLA's rules turn on the diabetes treatment, not on Foundayo. Its fitness-to-drive guidance groups GLP-1 agonists with metformin, gliptins and SGLT2 inhibitors: car and motorcycle drivers need not notify DVLA if they meet its conditions, which include regular medical review and no disqualifying complications of diabetes; bus and lorry drivers must notify DVLA whatever the medicine.

Insulin is different: GOV.UK says car and motorbike drivers must tell DVLA if insulin treatment lasts, or will last, over three months, or if they get, or are told they risk, disabling hypoglycaemia; bus, coach and lorry drivers must stop driving and tell DVLA when it starts. Sulfonylureas and glinides are "tablets carrying hypoglycaemia risk": car drivers need not notify DVLA provided, among other conditions, they can recognise a hypo in time to stop safely and have had fewer than two severe hypos while awake in 12 months. A severe hypo (one needing another person's help) at the wheel means stopping driving and notifying DVLA. The NHS adds: check before each journey and every two hours while driving, and do not drive for at least 45 minutes after a hypo has been corrected.

What to tell the prescriber

  • Whether you have diabetes and every medicine you take for it: insulin and which kind, any sulfonylurea, metformin, an SGLT2 inhibitor.
  • How you monitor your glucose and whether you notice your hypos; the NHS says to see a GP if they are frequent, severe, at night or unrecognised.
  • What you drive, if anything.
  • How regularly you eat and drink alcohol: the NHS lists missed meals and alcohol without food among hypo causes, and the SmPC notes orforglipron decreases food intake.

Do not stop Foundayo or alter a diabetes medicine yourself: the leaflet says blood sugar can rise if someone with type 2 diabetes stops. Foundayo carries the black triangle for additional monitoring; report suspected side effects, including hypos, to the MHRA Yellow Card scheme. See also our dosage page and FAQ page.

Frequently asked questions

Can Foundayo cause low blood sugar if I do not have diabetes?

The SmPC gives no figure for people without diabetes; even in type 2 diabetes, low blood sugar without insulin or a sulfonylurea is uncommon. The leaflet says Foundayo lowers sugar only when levels are high, and the NHS says hypos are rare without diabetes; symptoms then merit a GP visit.

Will my insulin or sulfonylurea dose change when I start Foundayo?

It may. The SmPC says a reduction in the sulfonylurea or insulin dose may be considered to reduce hypoglycaemia risk, stepwise for insulin and guided by blood glucose self-monitoring. The prescriber decides; do not change a dose yourself.

Do I need to tell DVLA that I take Foundayo?

It depends on your licence and diabetes treatment, not on Foundayo itself. For a car or motorcycle licence, GLP-1 agonists sit in the group whose drivers need not notify DVLA if its conditions are met; insulin and some tablets have their own rules, and bus and lorry drivers must notify DVLA for any diabetes medicine. If unsure, ask your doctor or nurse, as GOV.UK advises.

Should I stop Foundayo if I have a hypo?

Not on your own. The leaflet says not to stop Foundayo without talking to your doctor, and that with type 2 diabetes your blood sugar can rise if you stop. Tell your prescriber about any hypo and consider a Yellow Card report.

Sources

  1. Foundayo film-coated tablets — Summary of Product Characteristics (sections 4.2, 4.4, 4.5, 4.7, 4.8 and 5.1; revised 10 August 2026). emc. medicines.org.uk
  2. Foundayo film-coated tablets — Patient Information Leaflet (sections 1 to 4; revised August 2026). emc. medicines.org.uk
  3. NHS. Low blood sugar (hypoglycaemia). nhs.uk
  4. GOV.UK. Diabetes and driving. gov.uk
  5. DVLA. Diabetes mellitus: assessing fitness to drive. gov.uk
  6. MHRA Yellow Card scheme. yellowcard.mhra.gov.uk

Related reading